CDK4 and breast cancer: We next examined whether the alteration of the G1/S transition cooperative cascades is also observed in the combined CDK4/6i (palbociclib) and fulvestrant-resistant ER+ BC cell model, which is the sequential treatment upon progression on AI-monotherapy.